期刊文献+

济宁市CHB患者乙型肝炎病毒基因型特点及耐药性分析 被引量:2

Detection and analysis of hepatitis B virus genotype and drug resistance in CHB patients in Jining
原文传递
导出
摘要 目的检测分析济宁市慢性乙型肝炎(CHB)患者乙型肝炎病毒(HBV)的基因型特点、对5种抗病毒药物的耐药情况及耐药基因变异情况,为临床防治提供依据。方法选取2015年12月至2018年8月济宁市传染病医院收治的78例CHB患者的血清,用实时荧光定量分析仪检测HBV-DNA;巢式聚合酶链式反应(PCR)扩增HBVP区基因特异性片段,P区基因耐药相关位点采用Sanger测序法检测;采用AU5800全自动生化仪检测丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST),RT-6100酶标仪检测乙肝标志物。结果检出B型23例(29.48%),C型49例(62.82%),B+C混合型4例(5.13%),未分型2例(2.56%)。血清HBV-DNA载量、ALT、AST在B、C型中比较差异未见统计学意义(P>0.05);HBeAg、HBeAb阳性率在B、C型中比较差异未见统计学意义(P>0.05)。对5种抗病毒药物的敏感性:阿德福韦酯、替诺福韦酯敏感性最高,为66.67%,与其他3种药物比较差异有统计学意义(χ^2=49.98,P<0.05);恩替卡韦敏感性下降达34.62%,与其他4种药物比较差异有统计学意义(χ^2=7.29,P<0.05)。耐药性方面:替比夫定耐药率最高,为51.28%,拉米夫定耐药率为47.77%,与其他3种药物比较差异有统计学意义(χ^2=31.05,P<0.05)。结论济宁市CHB患者病毒基因型有B型、C型、B+C型及未定型,以C型为主,B型次之。抗病毒药物中阿德福韦酯、替诺福韦酯敏感性较高,替比夫定、拉米夫定耐药率较高。提示用耐药位点不同的两种药物协同治疗,有利于提高患者疗效。 Objective To detect and analyze the characteristics of hepatitis B virus(HBV)genotype,and drug resistance and drug resistance gene mutation to 5 kinds of antiviral drugs in patients with chronic hepatitis B(CHB)in Jining City,so as to provide a basis for clinical prevention and treatment.Methods Serum samples of 78 CHB patients admitted to Infectious Diseases Hospital of Jining from December 2015 to August 2018 were selected.HBV-DNA was detected by real-time fluorescence quantitative analyzer.Nested polymerase chain reaction(PCR)amplified P region gene specific fragments of HBV.And drug resistance related sites in P region gene were detected by Sanger sequencing method.Alanine aminotransferase(ALT),aspartate aminotransferase(AST)and hepatitis B markers were detected by AU5800 automatic biochemical analyzer and RT-6100 enzyme marker.Results Twenty-three cases(29.48%)of type B,49 cases(62.82%)of type C,4 cases(5.13%)of mixed type B+C and 2 cases(2.56%)of non-classification were detected.There was no significant difference in serum HBV-DNA load,ALT and AST between type B and type C(P>0.05),and the positive rates of HBeAg and HBeAb were not different between type B and type C(P>0.05).Adefovir dipivoxil and tenofovir dipivoxil had the highest sensitivity(66.67%),which was significantly different from the other three drugs(χ^2=49.98,P<0.05).The sensitivity rate of entecavir decreased by 34.62%,which was statistically different from the other four drugs(χ^2=7.29,P<0.05).The resistance rate of telbivudine was the highest(51.28%),and the resistance rate of lamivudine was 47.77%,both of which were statistically different from the other three drugs(χ^2=31.05,P<0.05).Conclusions The viral genotypes of CHB in Jining are type B,type C,type B+C and un-formed,with type C as the main type followed by type B.Among the antiviral drugs,adefovir dipivoxil and tenofovir are more sensitive,and the resistance rates of telbivudine and lamivudine are higher.It is suggested that the two drugs with different drug resistance sites can be synergistically given to patients to improve the curative effect.
作者 杨玉林 刘梅 Yang Yulin;Liu Mei(Infectious Diseases Hospital of Jining,Jining 272031,China)
出处 《中国实用医刊》 2019年第9期29-32,共4页 Chinese Journal of Practical Medicine
关键词 慢性乙型肝炎 基因型 耐药性 Chronic hepatitis B Genotype Drug resistance
  • 相关文献

参考文献5

二级参考文献48

  • 1于红缨,邵凌云,符政远,蒋建勇,王菲菲,王金蕾,孟成艳,张文宏.湖南省怀化市少数民族及汉族慢性乙型肝炎患者病毒基因分型及临床分析[J].中华实验和临床感染病杂志(电子版),2008,2(1):44-49. 被引量:8
  • 2刘林华,陈新月.阿德福韦酯抗乙肝病毒治疗进展[J].国外医学(病毒学分册),2005,12(5):154-157. 被引量:42
  • 3张继明.乙型肝炎病毒对拉米夫定的耐药性及防治[J].中国实用内科杂志,2007,27(11):894-897. 被引量:5
  • 4Yatsuji H,Noguchi C,Hiraga N,et al.Emergence of a novel lami-vudine-resistant hepatitis B virus variant with a substitution outsidethe YMDD motif[J].Antimicrob Agents Chemother,2006,50(11):3867-3874.
  • 5Schildgen O,Sirma H,Funk A,et al.Variant of hepatitis B viruswith primary resistance to adefovir[J].N Engl J Med,2006,354(17):1807-1812.
  • 6Lai CL,Leung N,Ten EK,et al.A l-year trial of telbivudine,lami-vudine,and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B[J].Gastroenterology,2005,129(2):528-536.
  • 7Allen MI,Deslauriers M,Andrews CW,et al.Identification andcharacterization of mutations in hepatitis B virus resistant to lamivu-dine.Lamivudine Clinical Investigation Group[J].Hepatology,1998,27(6):1670-1677.
  • 8Lok AS,Zoulim F,Locarnini S,et al.Antiviral drug-resistant HBVstandardization of nomenclature and assays and recommendations formanagement[J].Hepatology,2007,46(1):254-265.
  • 9Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovirdipivoxil for the treatment of hepatitis B e antigen-negative chronichepatitis B[J].N Engl J Med,2003,348(9):800-807.
  • 10Schiff ER,Lai CL,Hadziyannis S,et al.Adefovir dipivoxil therapyfor amivudine-resistant hepatitis B in pre-and post-liver transplanta-tion patients[J].Hepatology,2003,38(6):1419-1427.

共引文献28

同被引文献18

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部